
MPR Weekly Dose Podcast Episode 32
There has been a lot of recent developments in possible COVID-19 treatments. I'll go over the latest status with remdesivir, hydroxychloroquine, sarilumab, and remestemcel-L, and also the treatment gu...
30 Huhti 20209min

MPR Weekly Dose Podcast Episode 31
On today's podcast we run through the top COVID-19 stories including a steep rise in poison control calls; the authorization of an at-home testing kit; The hydroxychloroquine trial that's beginning so...
23 Huhti 20207min

MPR Weekly Dose Podcast Episode 30
We run through the latest COVID-19 news including results from a remdesivir trial; The blood purification system OK'd for patients in the ICU; A chloroquine trial halted early due to deaths; The saliv...
17 Huhti 20206min

MPR Weekly Dose Podcast Episode 29
This week we run through the latest COVID-19 news including the shortage of critical meds, The CDC U-turn on face mask recommendations, Remdesivir trial enrollment, testing for COVID-19 antibodies, an...
9 Huhti 20208min

MPR Weekly Dose Podcast Episode 28
This episodes covers the latest COVID-19 news including drug shortages, a new point-of-care diagnostic tool, the role of vitamin C, misuse of non-pharmacological chloroquine, and also some big news ab...
3 Huhti 20206min

MPR Weekly Dose Podcast Episode 27
This week we talk about the latest on COVID-19, including the virus in relation to NSAID use; the pandemics knock on effect on drug shortages; a safety alert for fecal microbiota transplants; and pote...
27 Maalis 20207min

MPR Weekly Dose Podcast Episode 26
This week we talk about a phase 1 vaccine trial for COVID-19 underway in Seattle; Concerns over COVID-19 and ACE inhibitor, ARB use; Safety labeling changes for SGLT2 inhibitors; A biosimilar to Herce...
20 Maalis 20205min

MPR Weekly Dose Podcast Episode 25
Today we talk about the latest COVID-19 news; New approvals for chronic fibrosing interstitial lung diseases and Cushing disease; and stronger safety warnings for montelukast.
12 Maalis 20207min






















